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A B S T R A C T The first known step in steroid hormone action is the association of the steroid with specific cytoplasmic steroid-binding proteins (SBP) . Using a competitive binding assay, we detected, quantified, and partially characterized such a SBP in cytosol from glucocorticoid-sensitive human lymphoblastic leukemic blasts. The affinity of steroids for the SBP was directly related to their known killing potency. For example, steroids without glucocorticoid effect such as androstenedione) etiocholanolone, and tetrahydrocortisol were unable to displace radiolabeled dexamethasone from the SBP in the binding reaction. The dose-response curve for in vitro inhibition of [ 'H]thymidine uptake in leukemic blasts correlated closely with the binding affinity of glucocorticoids to the SBP, providing additional support for an essential physiologic role for SBP in steroid action. SBP activity was either greatly diminished or absent in glucocorticoid-resistant cells. Six patients who intially had SBP in their blasts and were responsive to combinations of drugs including glucocorticoids no longer had SBP activity detectable at a time when they no longer responded to combinations of drugs including glucocorticoids. In vitro [8H]thymidine uptake was not inhibited by steroids in leukemic blast cells lacking SBP activity. Other patients who had received some antileukemic therapy including glucocorticoids and who still had SBP in their leukemic blasts, were still responsive to drug combinations that included glucocorticoids. This appears to be the first study demonstrating glucocorticoid receptors in a human tissue.
INTRODUCTION
The binding of steroid hormones to highly specific, high affinity cytoplasmic receptor proteins has been suggested as the first step in steroid hormone action in many systems (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . These steroid-binding proteins (SBP)1 appear to be the determinant of target tissue specificity (4, 6, 7, 12) . In such cells, the kinetics of association and dissociation between steroid and SBP are compatible with observations of the time course of hormone action (10, 13, 14) . Furthermore, the affinity of various steroids for a given target cell SBP correlates well with known biologic potency of the steroid in that system (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . A SBP has been demonstrated in cytosol from rat, thymocytes (8) . When those cells are exposed to glucocorticoid in sufficient concentration to bind significantly to this SBP eventual cell lysis results (12) . Various mouse lymphoma lines, which have been propagated in culture and which are lysed by glucocorticoids, have also been shown to have cytoplasmic SBP (18, 23) .
In steroid-resistant cell lines derived from these lymphomas, marked decreases in SBP were found (18, 19) . Others have reported decreases in SBP activity accompanying loss of steroid responsiveness in cultured hepatoma cells (24) and mouse fibroblasts (5, 25) . Recently, a promising attempt has been made to correlate estrogen responsiveness of human breast carcinoma in vivo to the presence of specific cytoplasmic estrogen-binding receptor proteins present in tumor homogenates (26) . It therefore seemed appropriate to investigate whether human leukemic lymphoblasts might contain an identifiable SBP.
'Abbreviations used in this paper: SBP, steroid-binding protein; PBS, phosphate-buffered saline pH 7.4; ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CLL, chronic lymphocytic leukemia.
Glucocorticoids have been used in the therapy of acute leukemia for years (27) (28) (29) . Many investigators have studied the mechanism of glucocorticoid effect in normal and leukemic lymphoid tissue (30) (31) (32) (33) (34) (35) (36) (37) (38) . Unfortunately in some cases the doses used have been so large that the responses may well have been due to nonspecific effects (13, 34) . Normal human lymphocytes are glucocorticoid resistant compared with lymphocytes from mouse and rat (30, 34) . Studies of glucocorticoid effect in human normal and neoplastic lymphoid tissue have been concerned with alterations in uptake of energy substrate or energy-substrate utilization (31) , changes in uptake of amino acids (39) , and decreased incorporation of amino acids and nucleosides into macromolecules (32-34, 37, 38) . Overall, tests of this kind have proven to be both time consuming and somewhat disappointing in assessing glucocorticoid response.
We therefore undertook an investigation of human acute lymphoblastic. leukemic (ALL) blasts, a tumor with known glucocorticoid responsiveness, in an attempt to identify, quantify, and characterize a SBP. The significant morbidity and mortality associated with glucocorticoid therapy, particularly in the treatment of human malignancy is well known (40) . With This greatly exceeds the concentration of plasma-free cortisol with which the SBP is in equilibrium since transcortin has a higher affinity -for cortisol than does the SBP (see below). At might be anticipated, binding of glucocorticoids to lymphoblast SBP is insignificant at normal physiologic levels of glucocorticoid (43, 44) at 4°C. In studies of SBP in rat thymocytes (13, 45) , hepatoma cells (10) , and mouse fibroblasts (46) A 20 min preincubation at 220C with dexamethasone and either trypsin (1 mg/ml) a chymotrypsin 100 ,ig/ ml, papain (1 mg/ml), or protease (1 mg/ml) completely destroyed all binding activity. Incubation with muramidase (500 ,Ag/ml), deoxyribonuclease (bovine pancreas 100 Ag/ml), ribonuclease (bovine pancreas 100 iglml) phospholipase A (100 /Ag/ml), phospholipase C (500 Ag/ml), and phospholipase D (500 Aog/ nml) had no effect on binding. Therefore, the receptors appear to be proteins and are referred to as such in this report. HgCl2 (10-' MI), Triton X-100 (0.4%), NaCl (150 mM) and KCI (1 M) completely destroyed binding activity whereas up to 25% glycerol or 5% ethanol had no effect on the extent of the binding reaction.
Kinetics of the specific cytoplasmic steroid-binding reaction. The association and dissociation reactions for one patient from whom large amounts of material were available were studied. Fig. 5A shows the time course of specific binding of dexamethasone to SBP at 4°C for six different steroid concentrations. It can be seen that for concentrations of steroid sufficient to saturate the SBP, the reaction has approached equilibrium after 2 h.-In the binding reaction, dexamethasone (Fig. 5B) , consistent with second order kinetics in the binding reaction (55) . Similar straight lines are obtained for the other steroid and receptor concentrations shown in Fig. 5A . From the slope of this line, the association rate constant (K1) may be calculated to be 3.5 X 107M-'min"'.
The dissociation reaction of the dexamethasone SBP complex was also studied. After allowing the SBP to become saturated with radiolabeled dexamethasone, a 1,000-fold excess of nonradioactive dexamethasone was added as a chase and specifically bound counts determined. The rapid decrease in specifically bound counts, even at 4°C, shown in Fig. 6A, demonstrates is assumed that the dissociation reaction follows first order kinetics, then a plot of logio (bound steroid concentration) vs. time should be linear (55) as shown in Fig. 6B . From the slope of this line dissociation rate constant of 1.73 X 10-' min-' is obtained. From the dissociation and association rate constants, an overall equilibrium (dissociation) constant of 0.5 X 10-' M can be calculated for the binding reaction as compared with 7 X 10-9 M which was obtained from the equilibrium data for dexamethasone which is not shown. Affinity of SBP for other steroid analogs. The affinity of various steroids for the SBP was studied in cells from the same patient described in the section above by measuring the ability of competing steroid analogs in 100-fold excess to compete with ['H]dexamethasone in the binding reaction. The concentration of dexamethasone used was 3.8 X 10' M. If target tissue specificity is universally determined by SBP, one would expect there to be a good correlation between binding affinity and biologic effect. Table I (9) . The excellent correlation between binding to this lymphoblast SBP and activity in other lymphoid systems is apparent. The close agreement between steroid analogs in terms of "inhibitory" effects in lymphoid tissue and stimulatory effects in liver is also of interest. Exceptions to the rule are progesterone and cortexolone which show a marked discrepancy between binding and biologic effect. This is consistent with the observation that association with receptor is only the first of several steps between binding and biologic response (8) . There is evidence that the receptor must undergo a temperature-dependent transformation after association with the steroid before uptake by the nucleus can occur (8, 11, 17, 56, 57) , a step that does not occur with progesterone and cortexolene (8, 10) . Such steroids have therefore been termed "anti-inducers" (21) .
DISCUSSION
The present studies reveal that human acute leukemic lymphoblasts from patients still responsive to steroid therapy contain a cytoplasmic protein capable of binding glucocorticoids with an affinity appropriate to the response of these cells to steroids. Furthermore, the kinetics of association and dissociation described in the present study are adequate to allow for the known time course of steroid effect in these cells (8, 21, 22, 31, 54, 58, 59) . The steroid-unresponsive cells examined in this study lack binding activity. These findings suggest a physiologic role for this SBP in glucocorticoid action in humans. As previously mentioned, highly specific steroid-receptor molecules have been found in many other steroid-responsive tissues. For reasons which are not clear however, when steroid unresponsiveness occurs, it is frequently the initial binding step which appears to be affected (5, 15, 18, (24) (25) (26) . For example, Pratt and Ishii found that mouse fibroblasts which were no longer growth inhibited by glucocorticoids had a loss of 80-90% of steroid-binding activity (25) . They and co-workers have succeeded in partially characterizing this SBP as a high molecular weight ( 620,-000) substance containing both protein and phospholipid based on its sensitivity to phospholipase as well as proteases (46) . The lymphoblast SBP described here was not sensitive to phospholipase action under the conditions we employed. Rosen, Fina, Milholland, and Rosen studied a transplantable lymphocarcoma (P1798) which was glucocorticoid responsive (59) . Repeated treatments with cortisol led to the emergence of a resistant tumor line which showed a decrease of over 90% in detectable cytoplasmic steroid-binding molecules. Aronow and Gabourel first developed a hydrocortisone-resistant subline of a mouse lymphoma in vitro (60) . Using a similar technique, Baxter, Harris, Tomkins, and Cohn studied several mouse lymphoma lines in culture which are lysed by glucocorticoids. Glucocorticoid-resistant cells appeared in their cultures with a frequency of 10V-101 (19) . In these resistant cells cytoplasmic steroid-binding activity was found to be reduced from 50 to 90% (19) . Rosenau, Baxter, Rous- seau, and Tomkins were able to separate the cytoplasmic-binding step from nuclear uptake of steroid (18) . By recombination experiments they showed that nuclei from steroid-resistant cells took up steroids normally when mixed with cytoplasm from sensitive cells whereas nuclei from steroid-sensitive cells did not show uptake of steroid when mixed with cytoplasmic extract derived from resistant cells. There has been much recent interest in the responses of lymphoid cells to glucocorticoids (17, 22, 31-39, 54, 57-67) . Some early events in the action of steroids on lymphoid tissue have included a decreased uptake of substrate, particularly glucose (17, 31, 62, 63) , decreased transport of amino acids (39, 64) and decreased incorporation of precursor small molecules into protein and nucleic acids (22, 32, 33, 37, 38, 53) . All of these early effects apparently require protein and RNA synthesis in that they can be inhibited by actinomycin D and cycloheximide (39, 57) . This has led to the hypothesis that some key RNA or protein factor is induced by steroid interaction with the nucleus (8, 68) .
Several previous attempts have been made to measure in vitro cytotoxicity of steroids using one of the above parameters (30, 32, 33, (36) (37) (38) (39) . Schrek incubated normal lymphocytes and those from patients with chronic lymphocytis leukemia (CLL) with prednisolone for 7 days, estimating cell viability at the end of the incubation (30) . He observed variable cytotoxicity in CLL cells. Normal lymphocytes usually remained viable during the study. This is consistent with our observation of minimal binding activity in normal lymphocytes. Claman, Moorhead, and Benner have also reported a high degree of steroid resistance in human (27, 28, 40, 69, 70) . This is consistent with our observation of the presence of binding protein in the untreated newly diagnosed group of patients. There is ample evidence that several antileukemic drugs used in combination may provide a more effective therapeutic regimen (29) We must emphasize that further prospective study will be necessary to prove whether a determination of SBP will provide an accurate prediction of glucocorticoid effect in ALL blasts. It will he noted that initially all patients with ALL had SBP detectable in their lymphoblasts. This correlates well with the fact that steroids will have an ameliorating effect in most untreated patients with ALL. We would expect that in the future, at least some previously untreated patients may present with cells lacking SBP activity.
[3H]Thymidine incorporation was inhibited by steroids in all five of the untreated patients studied in this way. The origin of the steroid-resistant lymphoblasts which inevitably seem to arise in patients receiving repeated courses of therapy remains unknown. Whether they arise from a preexisting subpopulation which eventually overgrows or from variants arising due to therapy must still be discovered. Cultured lymphocytoid cells (18) gave rise to resistant cells at a rate too high to be compatable with simple recessive mutations in a diploid locus. This kind of phenomenon has also been described by others (72) . Pursuit of this baffling problem in mammalian genetics is important in seeking more effective means of drug therapy.
In patients with acute myeloblastic leukemia (AML), the response rate to glucocorticoids is much lower and then only at relatively high doses of drug (27, 28, 40, 68) . One might therefore hope that if an SBP were detectable in AML, binding studies on untreated patients might be able to identify steroid-responsive patients and even provide some guidelines for doses needed to saturate the SBP. In preliminary studies, we have found that cytoplasmic extracts from myeloblasts of previously untreated patients frequently have no glucocorticoid-binding activity whereas extracts from a few patients have SBP activity. The significance of these findings awaits further observations.
